Empagliflozin attenuates pulmonary vascular hemodynamic progression and improves right ventricular adaptation in overcirculation-induced pulmonary hypertension
Right ventricular (RV) failure is the principal determinant of prognosis in pulmonary arterial hypertension (PAH). While current therapies primarily target pulmonary vasoconstriction and vascular remodeling, no treatment directly addresses RV maladaptation. Sodium–glucose cotransporter-2 (SGLT2) inhibitors exert...